Novartis Releases 2014 Corporate Responsibility Performance Report

Novartis Releases 2014 Corporate Responsibility Performance Report

Thursday, May 28, 2015 - 12:00pm

CONTENT: Press Release

May 28, 2015 /3BL Media/ - Novartis has published its Corporate Responsibility (CR) Performance Report for 2014.

In response to feedback received from stakeholders on the company’s 2013 CR Performance Report, the 2014 CR Performance Report offers additional historical data and further consolidation of CR information, as well as an enhanced narrative to provide context for Novartis CR reporting.

Novartis has a strong history of CR activities and has publicly reported on its performance since 2000 through its Annual Report as well as online and printed materials. The 2014 CR Performance Report again uses best-in-class Global Reporting Initiative G4 guidelines.

Novartis CR achievements in 2014 include:

  • Provided medicine to more than 72.4 million patients through access programs and ranked fourth in the Access to Medicine Index 
  • Published clinical study results for KAE609, the first antimalarial treatment with a novel mechanism of action to reach Phase II clinical development in more than 20 years
  • Reached 6.6 million people with health education through “Healthy Family” Social Ventures in India, Kenya and Vietnam
  • Established a dedicated Access to Medicine Committee to advance the goal of making healthcare more accessible to more people
  • Trained more than 122 000 Novartis associates on the company’s Code of Conduct
  • Reduced greenhouse gas emissions by 12.1% since 2008, while Novartis business has grown by 21%
  • Strengthened governance of CR through formation of the Governance, Nomination and Corporate Responsibilities Committee of the Board of Directors to oversee Novartis strategy and governance on CR-related issues

Download the Novartis 2014 CR Performance Report

Send your feedback:

Contribute to future Novartis reporting: share your views for an update of the Novartis CR materiality analysis


Esther Bares
Novartis CR Reporting